Australia markets close in 1 hour 41 minutes

Novartis AG (NVS)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
93.08-0.12 (-0.13%)
At close: 04:00PM EDT
93.15 +0.07 (+0.08%)
After hours: 06:04PM EDT

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees76,057

Key executives

NameTitlePayExercisedYear born
Dr. Vasant Narasimhan M.D.Chief Executive Officer8.03MN/A1976
Mr. Harry KirschChief Financial Officer4MN/A1965
Mr. Victor BultoPresident of US3.29MN/A1978
Dr. Patrick Horber M.D.President of International7.32MN/A1970
Dr. Steffen Lang Ph.D.President of Operations2.34MN/A1967
Paul PenepentHead of Group Financial Reporting and AccountingN/AN/AN/A
Dr. Samir Shah M.D.Global Head of Investor RelationsN/AN/A1962
Dr. Klaus Moosmayer Ph.D.Chief Ethics, Risk & Compliance Officer1.56MN/A1968
Ms. Karen L. HaleChief Legal Officer2.35MN/A1968
Dr. Robert Kowalski Pharm.D.Chief People & Organization Officer2.11MN/A1968
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Corporate governance

Novartis AG’s ISS governance QualityScore as of 1 April 2024 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.